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Abstract
The primate specific 82-kDa choline acetyltransferase (ChAT) isoform is
found in the nuclei of cholinergic neurons, with a disruption in the subcellular
localization in aging and AD brain samples# The functional significance of this
protein is poorly understood.

Previous studies have revealed a potentially

protective role for 82-kDa ChAT, mediated through a reduction in amyloid-!1-42
(A!1-42) release in APP/PS1 double transgenic primary cortical neurons. Here we
examine the effect of 82-kDa ChAT expression in transgenic neurons, on the
amyloidogenic processing of amyloid precursor protein (APP) and A! production.
In this study we demonstrate 82-kDa ChAT transcriptionally increases golgilocalized "-ear-containing ARF-binding 3 (GGA3), a protein that traffics BACE1 to
the lysosome for degradation.

Increased GGA3 expression coincides with a

reduction in BACE1 protein and activity levels, which may account for the
reduction in A!1-42 production. These findings indicate a potential regulatory
function of 82-kDa ChAT, specifically at the genetic level.

Keywords
Choline acetyltransferase, Alzheimer’s disease, golgi-localized "-ear-containing
ARF-binding, !-site APP cleaving enzyme
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Chapter 1: Introduction

1.1

Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurological disorder and the

leading cause of age-related cognitive disability, characterized by a loss of
memory and cognitive function. AD currently accounts for 50%-80% of the total
cases of dementia among patients over the age of 65. The prevalence of AD is
continuing to rise with the increase of the aging population, creating financial
pressure on the healthcare system. It is predicted that by 2050 the annual cost
of caring for individuals with AD will increase from $203 billion to over $1.2 trillion
in the USA alone. In a report published by the Alzheimer Society of Canada
entitled “The Rising Tide”, the magnitude of the problem faced by the Canadian
health care system and society of caring for individuals with age-related diseases
was presented. It is predicted that by the year 2030, the number of Canadians
with AD will be at least 1.1 million, costing at least $153 billion dollars per year to
provide care to these individuals, and involve at least 756 million hours of
informal caregiving time for families and other unpaid helpers.
Patients with the disease live an average of 10 to 12 years after symptoms
become noticeable, but the duration of the disease can range from 4 to 20 years,
depending on the diagnosis and management.

An increasing number of

individuals are being diagnosed with early-onset or familial AD, where symptoms

!

#!

are seen by patients 40 to 50 years of age. Familial forms of AD are linked to
mutations in either amyloid precursor protein (APP), or presenilin 1 (PS1) and
presenilin 2 (PS2), components of the !-secretase complex (Octave et al., 2008),
resulting in elevated "-amyloid peptide (A") levels or altered A" production
favouring the release of toxic A"1-42 (Citron et al., 1992, Jankowsky et al., 2004).
Inheritance of the !4 allele of apolipoprotein E (APOE) increases the risk for
developing dementia and lowers the age of onset of the sporadic form of AD.
The mechanism by which this mutation affects the risk and age of onset of AD is
currently unknown, but the prevailing evidence suggests that it is related to
increased A" aggregation and decreased A" clearance (Kim et al., 2009).

1.2

Etiology of AD
The initiating cause of AD is still unknown, but the pathogenesis of the

disease has long been linked to the formation of the ~4-kDa A", its deposition as
amyloid plaques, and to intracellular neurofibrillary tangles (NFTs). Research
into the APP processing pathway and the link between mutations in the PS1
genes has lead to the amyloid hypothesis becoming a main focus of AD
research. More recent studies have only strengthened the association between
the amyloid hypothesis and the prevalence of AD. First, large depositions of
hyperphosphorylated tau protein in NFTs are also found in brains of patients
diagnosed with Parkinson’s disease, with this being caused by mutations in the
gene encoding the tau protein and resulting in profound neurodegeneration.

!
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These patients do not have deposition of amyloid plaques and display few of the
other characteristics of AD, demonstrating a fundamental role for A" in AD
pathogenesis (Hardy and Selkoe, 2002). Mutations in tau are also shown to
cause autosomal dominant frontotemporal dementia as well as amyotrophic
lateral sclerosis (Poorkaj et al., 2001). Second, transgenic mice that express
both mutant human tau and mutant human APP show increased levels of taupositive tangles compared to mice that express only mutant human tau. These
findings suggest that either APP or A" influences the formation of tau-positive
NFTs and are present prior to tangle deposition (Lewis et al., 2001). Finally,
genetic variability in A" breakdown and removal can contribute to the risk of lateonset AD (Ertekin-Taner et al., 2000)
Amyloid plaques are formed by the aggregation of 37-43 amino acid
fragments of A" within the brain parenchyma (De Strooper and Annaert, 2000).
A" is produced by an amyloidogenic processing pathway that involves sequential
enzymatic cleavage of the APP carried out by the membrane-bound "-site APPcleaving enzyme "-secretase (BACE1) and by the #-secretase complex
enzymes.

APP is first cleaved by BACE1 to produce a secreted sAPP"

polypeptide and a membrane bound C-terminal fragment (C99) (Vassar et al.,
1999).

The #-secretase complex then further cleaves C99 resulting in the

secretion of A".

Conversely, A" production can be interrupted by the non-

amyloidogenic pathway, in which APP is cleaved within the A" sequence by $secretase thereby releasing soluble APP$ and a membrane bound C-terminal
fragment

!
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Figure 1.1 APP processing through the amyloidogenic and nonamyloidogenic pathway.

Cleavage of APP in the amyloidogenic pathway

involves processing by both "-secretase (BACE1) and the !-secretase complex
which releases either a 40 or 42 residue A" peptide. The A" peptides begin to
aggregate forming soluble oligomers and overtime result in the formation of
amyloid plaques associated with Alzheimer’s disease.

Alternatively, APP

processing can occur through the non-amyloidogenic pathway, by which it is first
cleaved by #-secretase (ADAM10) and the !-secretase complex, avoiding the
formation of toxic A" peptides.

!
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(C83) (Vassar et al., 1999). The #-secretase complex further cleaves C83
resulting in the secretion of nonpathogenic p3 fragment (Figure 1.1).
The direct mechanisms by which extracellular A" exerts toxic effects on
cholinergic neurons are unknown, but A" aggregates are believed to severely
alter cholinergic synaptic transmission by reducing ACh synthesis and release
(Kar et al., 2004).

Nunes-Tavares et al (2012) investigated the effect of A"

oligomers on cholinergic neurons and found a major reduction in ChAT activity,
with no change in neuronal viability or total ChAT protein expression. A"-induced
oxidative stress appears to play a predominant role in this inhibition, which
appears to be mediated through an imbalance between reactive oxygen species
(ROS) production and antioxidant defense mechanisms. A" oligomers are able to
increase ROS levels in cholinergic neurons through a mechanism requiring Nmethyl-D-aspartate (NMDA) receptor activation (De Felice et al., 2007).
Consistent with this finding, both treatment with antioxidant polyunsaturated fatty
acids (PUFAs) and the NMDA receptor inhibitors MK-801 and memantine
prevents ChAT inhibition (Nunes-Tavares et al., 2012). Further study has shown
that insulin signaling down-regulates A" oligomer binding of the NMDA receptor
which resulted in a reduction of both ROS production and ChAT inhibition
(Nunes-Tavares et al., 2012). These results demonstrate a significant role of A"induced ROS toxicity on ChAT inhibition and cholinergic function in AD patients.

!
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GGA3 and BACE1 trafficking
The Golgi-localized #-ear-containing ARF-binding (GGA) family of proteins

are ubiquitously expressed and are involved in the trafficking of proteins from the
trans-Golgi network to the endosome/lysosome system (Ghosh and Kornfeld,
2004). Currently, there have been three GGAs discovered in mammalian cells
(GGA1, GGA2, and GGA3) (Boman et al., 2000). GGAs contain four distinct
domains: an N-terminal VHS domain (VPS27, Hrs, and STAM) that binds the
acidic di-leucine DXXLL motif; a GAT domain (GGA and Tom1) that binds
Arf:GTP; a hinge region that binds clathrin; and a COOH-terminal #-adaptin ear
region which functions to recruit accessory proteins (Kang et al., 2010). GGAs
mediate trafficking through the recognition of specific signal motifs. For example,
proteins that have been modified with the addition of mannose 6-phosphate
groups bind to the mannose 6-phosphate receptor (MPR) and are bound at the
VHS domain by GGAs through the recognition of the DXXLL motif located on the
carboxyl-terminal of the MPR (Johnson and Kornfeld, 1992). A key component
of the GGA trafficking pathway mediated through the DXXLL-VHS interaction are
the acid hydrolases that are shuttled to the lysosome (Doray et al., 2002).
BACE1 is a 501 amino acid type 1 transmembrane protein that is
ubiquitously expressed, with the highest level of mRNA and protein levels found
in neurons in the brain (Citron, 2004). As a member of the aspartyl protease
family, it contains an active protease site on the luminal side that has the ability
to cleave APP at the "-secretase cleavage site. This process is enhanced within
intracellular compartments of the secretory pathway, specifically the Golgi and

!
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endosomes, where the acidic pH optimizes BACE1 activity (Vassar et al., 1999).
Transport of BACE1 is mediated through the C-terminal fragment di-leucine
(DXXLL) sorting signal that is present on many transmembrane proteins.
The GGA3 GAT domain has been reported to bind ubiquitin and directly
facilitate the delivery of activated epithelial growth factor receptor (EGRF) to
lysosomes (Puertollano and Bonifacino, 2004). RNAi silencing of GGA3, but not
GGA1 or 2, results in the accumulation of EGRF that demonstrates a GGA3specific trafficking mechanism. This GGA3-mediated lysosomal trafficking has
also been reported to regulate BACE1 degradation. BACE1 has been shown to
be ubiquitinated at Lys-501, undergoing both monoubiquitination and also Lys63-linked polyubiquitination that facilitates its transport to and degradation in the
lysosomal system (Kang et al., 2010).

GGA3 is able to recognize and bind

directly with ubiquitinated BACE1 and target it for lysosomal degradation. This
process is independent of the GGA3 VHS domain or the BACE1 di-leucine motif,
as mutations in both these domains did not abrogate their binding.

Further

support of this interaction was demonstrated when Kang et al (2010) reported
BACE1 accumulation in early endosomes in H4 cells depleted of GGA3,
compared to control cells.
Several studies have focused on the expression and activity of BACE1
mRNA and protein levels in AD brains. It has been shown that BACE1 mRNA
levels remained unchanged (Tan and Evin, 2012), but there are significant
increases in BACE1 protein and activity levels, particularly in the temporal cortex
(Fukumoto et al., 2002; Kang et al., 2010). The increase in BACE1 protein may

!
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be associated with various post-translational modifications including the removal
of the pro-peptide, glycosylation, and phosphorylation (Li et al., 2006).
Conversely, in these brain regions with high levels of BACE1 expression, GGA3
levels were significantly reduced (Tesco et al., 2007). There is growing evidence
that BACE1 is a stress-induced protein, whereby elevated levels can be seen in
rodents following cerebral ischemia and traumatic brain injury (Walker et al.,
2012). Caspase-3 activation following these insults has been shown to elevate
BACE1 protein levels and activity though post-translational stabilization of
BACE1 (Tesco et al., 2007). Moreover, GGA3 is also a substrate of caspase-3
resulting in its cleavage and inactivation, thereby causing the increased BACE1
levels and activity and enhanced amyloidogenic processing of APP (Tesco et al.,
2007).

1.4

Cholinergic Neurons
The cholinergic hypothesis of AD implicates degeneration of both the

neurons and synapses that produce and release acetylcholine (ACh) as a major
cause of the cognitive impairment observed in AD patients. There appear to be
changes in ACh production in brain of AD patients related to impaired transport
of choline into cholinergic nerve terminals by the choline transporter (CHT) and
synthesis by the enzyme choline acetyltransferase (ChAT). A decline in ChAT
activity and loss of ChAT gene expression is found in regions affected by the
disease (Bird et al., 1983, Zambrzycka et al., 2002).

!
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Cholinergic neurons are an integral part of the mammalian brain, and play

an important role in cognitive function, including memory formation through the
action of the neurotransmitter ACh (Coyle et al., 1983, Francis et al., 1999).
Modest changes in cholinergic neuron function occur during normal aging, and
these changes are accentuated in neurological diseases such as AD and related
dementias. Although the degeneration of cholinergic neurons does not cause
AD, it plays a primary role in the clinical symptoms of AD. Cholinergic neuron
projections from the nucleus basalis of Meynert to the cortex and hippocampus
are particularly damaged in AD patients (Schliebs and Arendt, 2011).
Dysregulation of the cholinergic signaling cascade involving the expression and
function of the major cholinergic proteins, decreased ChAT, activity is an early
hallmark of AD (Nunes-Tavares et al., 2012). While there is no cure for AD, a
number of therapeutic interventions, both current and in the past, are focused on
treating the cholinergic neurotransmitter deficits. Early treatments focused on the
replacement of ACh precursors (choline or lecithin), but these failed to increase
overall cholinergic activity (Francis et al., 1999).

A more recent and well

developed therapeutic approach focuses on the use Aricept (Pfizer), Exelon
(Novartis) and Reminyl (Janssen), which are inhibitors of the enzyme
acetylcholinesterase (AChE). These drugs work by decreasing the activity of
AChE, thereby preventing the hydrolysis of ACh to choline and acetate and
prolonging the existence and effect of ACh at the synapse.

!
1.5

"+!
Choline Acetyltransferase
ACh, a critical mediator of neuronal communication, is produced in

cholinergic neuronal cytoplasm including nerve terminals by the ChAT catalyzed
combination of acetyl co-enzyme A (acetyl-CoA) and choline. ACh is transported
into synaptic vesicles by the vesicular acetylcholine transporter (VAChT) and,
upon neuronal depolarization, these vesicles fuse with the plasma membrane to
release ACh into the synaptic cleft where it binds to post-synaptic receptors.
AChE hydrolyzes ACh in the synaptic cleft to choline and acetate, from where
choline is immediately recycled back into the presynaptic terminal by the sodiumcoupled high-affinity CHT to serve as substrate for ACh re-synthesis.
Currently, seven isoforms of ChAT mRNA have been characterized in
humans: R1/2-, N1/2-, H-, S-, and M-transcripts (Gill et al., 2007) (Figure 1.2).
All human ChAT mRNAs translate a 69-kDa protein, but the S- and M-transcripts
also encode a 74- and 82-kDa isoform, respectively (Oda et al., 1992). Based on
immunohistochemical localization studies involving human necropsy tissues, it
has been reported that both 82-kDa and 69-kDa ChAT are expressed in
cholinergic neurons in the spinal cord, basal forebrain and putamen, as well as
an 82-kDa ChAT specific expression in the clastrum (Gill et al., 2007). The 69kDa enzyme is predominately localized to the cytoplasm of cholinergic neurons,
whereas the 82-kDa ChAT is found predominately in the nucleus. The 82-kDa
ChAT protein has two nuclear localization signals (NLSs), one of which is located
within its 118-amino acid residue amino-extension and one of which is in
common with the 69-kDa sequence, and this facilitates
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Figure 1.2. The cholinergic gene locus. The cholinergic gene locus contains
the coding sequences for multiple ChAT exons and VAChT. The human specific
M-ChAT transcript variant has two functional translation initiation sites resulting in
production of both 69- and 82-kDa ChAT proteins. The 82-kDa ChAT protein has
an extended amino terminus which contains a nuclear localization signal.
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trafficking of the protein through the nuclear pore complex (Gill et al., 2003).
Classical NLS (cNLS) sequences are rich in both of the basic amino acids
arginine and lysine (Tachibana et al., 1999).

Proteins in the cytoplasm

containing a cNLS sequence can be bound by the heterodimeric import receptor,
importin $/", which facilitates their translocation through the nuclear pore (Lange
et al., 2007). The NLS sequence found in the amino-terminal extension of 82kDa ChAT contains a basic region that is both necessary and sufficient for
nuclear localization of the enzyme (Resendes et al., 1999). Nuclear export of 69kDa ChAT and a small pool of 82-kDa ChAT is mediated through the recognition
of nuclear export signals (NES). These sites are typically rich in valine, leucine
and isoleucine residues (Tang et al., 1999).

Both isoforms of ChAT contain

NESs, but the majority of the 69-kDa ChAT nuclear export is mediated by the
leptomycin B-sensitive Crm-1 export pathway (Gill et al., 2003).
The subcellular localization of 82-kDa ChAT appears to change with
increasing age and in individuals diagnosed with mild cognitive impairment
(MCI). It was reported that there is an age-related alteration of the subcellular
distribution of 82-kDa ChAT, whereby individuals over the age of 80 years had
increased levels of cytoplasmic 82-kDa ChAT and decreased levels of nuclear
localized 82-kDa ChAT. Furthermore, this change in the subcellular localization
of 82-kDa ChAT expression is accentuated in MCI and AD patients. Currently,
the mechanism underlying the altered subcellular localization of 82-kDa ChAT in
cholinergic neurons during aging and in individuals diagnosed with MCI or early
AD is unknown. However, it is clear that any situation that alters ChAT activity
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will directly impact ACh synthesis and may result in reduced cholinergic
neurotransmission.
Previous work in our laboratory has focused on the role of nuclear 82-kDa
ChAT and how it relates to changes in gene expression and regulation. Through
microarray analysis, it was observed that ChAT expression resulted in a change
in the expression on several APP processing-related genes. Taken together, the
relationship between the changes in ChAT-mediated expression of these genes
led to a prediction of reductions in both BACE1 activity and A" production. More
recently, a study has focused on a secondary function of nuclear localized ChAT,
as a possible regulator of gene transcription.

Matsuo and coworkers (2010)

reported that overexpression of 82-kDa ChAT enhanced transcriptional activation
of the CHT1 gene in SH-SY5Y human neuronal cells. The mechanism behind
the transcriptional regulation by 82-kDa ChAT is still unknown, but there are
multiple possibilities by which this regulation could occur.

Nuclear ChAT

maintains its enzymatic activity and could result in the production of ACh in the
nucleus

and

activate

transcription

through

muscarinic

ACh

receptors.

Interestingly, both G-protein-coupled muscarinic ACh receptors (Lind and
Cavanagh, 1993) and nicotinic ACh receptors (Okuda et al., 1993) have been
detected in the nuclear envelope, however, these receptors are predicted to have
ligand binding sites that face the luminal side of the nuclear envelope, so
nuclear-synthesized ACh would not likely be able to successfully bind to these
receptors (Matsuo et al, 2011). A second possibility is that 82-kDa ChAT may
bind directly to certain DNA regions and act as a transcription factor. Based on
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analysis of the three-dimensional structure of ChAT (Kim et al., 2006), the protein
displays basic patches along its surface that are predicted to be capable of
binding DNA. The ability of 82-kDa ChAT to bind to DNA either directly or in
association with other proteins or nuclear components has not yet been
examined.

1.6

Transgenic Mouse Models of AD
The use of genetically-modified mice as a model of neurodegenerative

diseases can give a unique insight into the progression of these diseases. Early
transgenic models of AD were based on overexpression of APP to promote
increased levels of A" deposits (Andra et al., 1996), but the progression of these
deposits were slow, needing at least 10 months to develop amyloid plaques or
deficits in memory and learning.

More recent studies have involved the

development of transgenic mice that express a gain-of-function mutant form of
PS1 (Duff et al., 1996), but these mice also displayed very limited A" pathology
or cognitive impairment.

One of the most promising commercially-available

murine models of AD is the double transgenic APPswe/PS1dE9 mouse. These
mice were generated with mutant transgenes for APP (APPswe: KM594/5NL)
and PS1 (dE9: deletion of exon 9), driven by mouse prion protein (PrP) promoter
elements, which direct transgene expression within central nervous system
(CNS) neurons.

Plasmids containing each transgene were coinjected into

B6C3HF2 pronuclei and insertion occued at a single locus. The Swedish APP

!

"&!

mutant allows for greater A" production by promoting processing by the betasecretase pathway, while the PS1 mutant promotes A"1-42 production. These
mice have significant A" deposition beginning around 4 months with plaque
formation by 6 months (Garcia-Alloza et al., 2006).

1.7

Rationale
1) Previous work has demonstrated that overexpression of either 82-kDa
human ChAT or mutant R560H 82-kDa ChAT in cortical neurons derived
from APP/PS1 transgenic mice reduces the levels of A"1-42 released into
the culture media when compared to control neurons expressing GFP.
Further work has demonstrated that neuronal expression of 82-kDa ChAT
can alter expression of APP processing genes and levels of APP
processing proteins, leading to reduced overall BACE1 protein levels and
ultimately lowering A"1-42 production. These previous studies demonstrate
a novel role for 82-kDa ChAT, but the exact mechanism of 82-kDa ChAT
function was not investigated.

The goal of this study will identify the

cellular pathway through which 82-kDa ChAT reduces the level of A"1-42
release from APP/PS1 mouse cortical neurons.
2) A"1-42 toxicity is in part mediated by elevating cellular ROS levels which
leads to cellular dysfunction and eventual cell death. AD patients have a
marked increase in ROS levels and this is believed to contribute to the
neurodegeneration observed in the later stages of the disease. Cysteine
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(Cys) residues are particularly susceptible to oxidative toxicity, resulting in
the formation of disulfide bonds both within and between proteins. The
82-kDa ChAT protein has a higher than typical number of Cys residues,
and this could make the protein vulnerable and potentially readily oxidized
by ROS. The goal of this study is to investigate the effect or varying ROS
agents and concentrations on both the structure and subcellular
localization of 82-kDa ChAT.

1.8

Study: Effect of 82-kDa ChAT on A" production

Hypothesis:
1) Expression of nuclear 82-kDa ChAT in APP/PS1 transgenic neurons
regulates the expression of APP processing proteins, thereby promoting
the non-amyloidogenic pathway.
2) Exposure of neural cells to A" or oxidative stress causes alterations in
both 69- and 82-kDa ChAT structure, function and subcellular localization.
Specific Aims:
1) Determine the cellular mechanism that underlie the reduction in A" levels
in cortical neurons cultured from APP/PS1 transgenic mice that ectopically
express 82-kDa ChAT.
2) Identify the effects of A" and oxidative stress on both 69- and 82-kDa
ChAT structure, function, and localization

!

"(!

CHAPTER TWO: MATERIALS AND METHODS

2.1 Materials
The majority of the general laboratory chemicals used in these studies were
purchased from Sigma-Aldrich (St. Louis, MO, USA) and BioShop (Burlington,
ON, Canada). HEK293 and SH-SY5Y cells were acquired from American Type
Culture Collection (Manassus, VA, USA) and SN56 cells were a gift from Dr
Bruce Wainer (Emory University, Oxford, GA, USA).

Cell culture reagents:

Dulbecco’s modified eagle medium (DMEM), minimal essential medium (MEM),
and fetal bovine serum (FBS) were supplied by Invitrogen (Burlington, ON,
Canada). The REDExtract-N-Amp Tissue PCR Kit for genotyping and GeneElute
Kit for RNA isolation were purchased from Sigma-Aldrich. BioRad (Mississauga,
ON, Canada) supplied the iScript cDNA synthesis kit and iQ SYBR Green kit.
The "-secretase Activity Kit was from BioVision (CA, USA) and the LightSwitch
Luciferase assay system was purchased from SwitchGear Genomics (Menlo
Park, CA, USA). The human A"1-42 ELISA kit was purchased from Invitrogen
(Burlington, ON, Canada). Primary antibodies used for immunoblots include antiactin (1-19) and anti-ubiquitin (P4D1) were purchased from SantaCruz
Biotechnology Inc. (Santa Cruz, CA, USA), anti-GGA3 and anti-myc from Cell
Signaling (MA, USA), anti-Flag from Sigma-Aldrich, anti-APP from Millipore
(Billerica, MA, USA), anti-BACE1 (C-term) from Abcam (Cambridge, MA, USA)
and secondary anti-rabbit and anti-mouse horseradish peroxidase-conjugated
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(HRP)

antibodies

from

Jackson

Laboratories

(MA,

USA).

For

immunoprecipitation, anti-BACE (C-term, clone 61-3E7) was purchased from
Millipore and for immunocytochemistry, anti-NeuN (A60) and secondary
AlexaFluor conjugated antibodies were purchased from Millipore and Invitrogen
respectively. Enhanced ChemiLuminescence (ECL) immunoblot reagents were
obtained from GE Healthcare Life Sciences (Baie d’Urfé, QC, Canada) and
Clarity Western ECL substrate from BioRad. GFP and GGA3 shRNA lentiviral
particles were purchased from SantaCruz Biotechnology Inc.

2.2 Culture of Cell Lines
Multiple cell lines were used throughout this project, including HEK 293
(human embryonic kidney cells), Neuro-2A (N2A, mouse brain neuroblastoma
cells) SH-SY5Y (human neuroblastomas cells) and SN56 (rat medial septal
neuron immortalized by fusion with a mouse myeloma cell line) cells, which were
grown at 37° and 5% CO2 in a humidified environment. HEK 293 and N2A cells
were maintained in MEM supplemented with 10% FBS and 0.1% gentamycin.
SH-SY5Y and SN56 cells were grown in DMEM supplemented with 10% FBS
and 100 µg/mL penicillin-streptomycin.

SH-SY5Y cells transfected with a

plasmid encoding 82-kDa ChAT using Lipofectamine 2000 were selected for
stable transformants with 500 µg/mL G-418 (Geneticin) for 4 weeks. Stablyexpressing 82-kDa ChAT SH-SY5Y cells were maintained in 100 µg/mL G-418.
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2.3 Transgenic Mice and Genotyping
Heterozygous double transgenic male mice expressing APPswe and PS1dE9
in a C57/Bl6 background were bred with non-transgenic (NTG) female C57/Bl6
mice (Jackson Laboratories). The mouse colonies were maintained on a 12-hour
light and dark schedule, and all procedures were approved by the Animal Use
Subcommittee at Western University in accordance with the guidelines set out by
the Canadian Council on Animal Care.
Pregnant females were sacrificed at gestational day 15-16 and genotyping
of embryos was carried out using REDExtract-N-Amp Tissue PCR Kit (SigmaAldrich). Tail clippings from embryos were digested and DNA was extracted for
PCR amplification using primers (Table 2.1) specific for the two transgenes and
endogenous mouse ChAT gene promoter (FLOXG) as an internal control. The
amplified DNA was loaded onto a 1% agarose gel, and following electrophoresis
amplicons were visualized using Redsafe nucleic acid stain (iNtRON).

Table 2.1: Primers used for genotyping of APP/PS1 transgenic embryos
Target

Primer

FLOXG

Forward: GAGAGTACTTTGCCTGGGAGGA
Reverse: GGCCAGAGTAAGACCTCCCTTG
Forward: GACTGACCACTCGACCAGGTTCTG
Reverse: CTTGTAAGTTGGATTCTCATATCCG
Forward: AATAGAGAACGGCAGGAGCA
Reverse: GCCATGAGGGCACTAATCAT

APPswe
PS1dE9

Amplicon
Size
171 bp
350 bp
608 bp
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2.4 Cortical Neuron Cultures
Brains were removed from embryonic day 15 mouse embryos and cortices
dissected. Tissues were dissociated with trypsin at 37°C and triturated in a
DNAse solution with chicken egg white trypsin inhibitor. Cells were suspended in
Neurobasal medium supplemented with B27, N2, penicillin/streptomycin and Lglutamine, then plated on poly-L-ornithine coated 35-mm (1.6 x 106 cells/plate)
and 12-well (5 x 105) plates and maintained in culture for 8 days in vitro (DIV).
In some experiments, cortical neurons seeded on 35 mm culture plates
were treated with 25 µM chloroquine (Sigma) or vehicle for 18 hours prior to
experimentation.

2.5 ChAT-encoding Adenovirus Synthesis and Purification
Full-length human 82-kDa ChAT cDNA containing an EcoRI (GAATTC) site
at the amino-terminus and BgIII (GATCT) site at the carboxyl-terminus was
ligated into the pDC316 shuttle vector which contained the loxP site necessary
for recombination in the adenoviral genome. HEK293 cells were co-transfected
with the shuttle vector and the adenoviral genomic plasmid (Ad5 E1-deleted
adenovirus). Using Cre recombinase catalyzed site-specific recombination at the
loxP sites described by Ng et al. (1999) active adenovirus stocks were
generated. Virus expressing GFP and catalytically-inactive R560H 82-kDa ChAT
were also prepared.
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Adenoviral stocks were amplified for 10 DIV in HEK293 cells that provide

the E1 gene necessary for viral replication.

Cells were harvested and all

adenovirus was collected following 3 freeze-thaw cycles in 0.1M Tris-HCL (pH
8.0).

Active viral particles were purified through cesium chloride gradients,

aliquoted and stored at -80°C. Viral particle concentrations were determined with
a NanoDrop spectrophotometer at the optical density 260 nm (OD260) using the
formula infectious particles/mL = OD260 x 1012. The multiplicity of infection (MOI),
the number of infectious viral particles per cells plated, was calculated and it was
determined that an MOI of 100 produced the highest number of adenovirus
expressing cortical neurons without apparent toxicity.

2.6 Lentiviral Transduction of Cultured Neurons
Mouse cortical neurons were maintained at 37° and 5% CO2 in a
humidified environment for 3 DIV prior to infection with lentivirus encoding
shRNA targeting GGA3 transcripts (Santa Cruz).

Conditions for infection of

neuron cultures were optimized on a 12-well plate for cell density, infection time
and viral dose. Cortical neurons were seeded at 500,000 cells and infected with
10 µL of lentivirus preparations encoding either GFP control (copGFP) or shRNA
specific for GGA3 knockdown with no known cross-reactivity based on sequence
analysis.

Subsequently, cultured neurons were transduced with adenovirus

expressing either GFP, 82-kDa ChAT or R560H 82-kDa ChAT on 6 DIV for 48
hours followed by RNA and protein isolation.
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2.7 Immunoblots
Cells were washed with HBSS and lysed for 30 minutes at 4°C in 50 mM
Tris-HCl (pH 7.5) containing 150 mM NaCl, 0.5% Triton X-100, 1 mM AEBSF, 10
µg/mL leupeptin, 25 µg/mL aprotinin, 10 µg/mL pepstatin A and 700 units/mL
DNAse 1.

Protein concentrations were determined using a Bradford assay

(BioRad) and bovine serum albumin as a standard. Aliquots containing 50 µg of
total cell lysate protein were heated at 100°C for 5 min following the addition of
one-half volume of 3X Laemmli sample buffer (6% SDS, 0.1875 M Tris-HCl pH
6.8, 30% glycerol, 0.015% bromophenol blue, and 7.5% "-mercaptoethanol).
Proteins were separated on 10% SDS-PAGE gels, then transferred to PVDF
membranes. Membranes were blocked in 10% non-fat dry milk in wash buffer
(TBS, 0.01% Tween-20) for 1 hour at room temperature.

Membranes were

incubated in primary antibody (Table 2.2) in wash buffer with 5% non-fat dry milk
or 5% BSA, overnight at 4°C. Membranes were washed and incubated with
horseradish peroxidase conjugated secondary antibody in wash buffer with 5%
non-fat dry milk for 1 hour at room temperature. Immunoreactive bands were
detected by Clarity western ECL substrate (BioRad) and visualized using a
Chemidoc (BioRad). Densitometric analysis was performed using Image Lab
software (BioRad) and individual Immunoreactive bands were normalized to
immunoblots of actin levels for each sample.
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Table 2.2: Antibodies used for protein detection
Target
Protein
Actin (1-19)
BACE1
GGA3
APP
Ubiquitin
ChAT Cterminal
ChAT Nterminal
Myc
Flag

Primary
concentration
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000

Secondary
Concentration
1:10,000
1:10,000
1:2500
1:2000
1:10,000
1:10,000

Host

Manufacturer

Rabbit
Rabbit
Rabbit
Mouse
Mouse
Rabbit

1:250

1:5000

Rabbit

1:1000
1:1000

1:10,000
1:10,000

Rabbit
Rabbit

Santa Cruz
Abcam
Cell Signaling
Millipore
Santa Cruz
Immunoaffinity
purified
Immunoaffinity
purified
Cell Signaling
Sigma

2.8 Immunofluorescence
To analyze the subcellular localization of 82-kDa ChAT, SH-SY5Y cells
were fixed in freshly prepared 4% paraformaldehyde-PBS for 30 minutes at room
temperature. Fixed cells were permeabilized with 0.5% Triton X-100 in PBS for 5
minutes, then blocked in PBS containing 3% normal goat serum for 30 minutes.
SH-SY5Y cells were stained for ChAT by incubating with an immunoaffinity rabbit
anti-ChAT antibody that recognizes 13 amino acids at the carboxyl-terminus of
the protein (cTAB, 1:1000) overnight at 4°C. Cells were then incubated with an
anti-rabbit secondary antibody conjugated to AlexaFluor 647 in blocking buffer
(1:1000) for 1 hour at room temperature. Nuclei were stained with Hoechst dye
(33342) in PBS (1:1000) for 5 minutes. Images were acquired with a Zeiss LSM
510 META laser-scanning confocal microscope using a 63X objective. Hoechst
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staining was visualized using 405 nm excitation and a 420-480 nm emission, and
82-kDa ChAT was visualized with a 647 nm excitation and 650 nm emission
using a long pass filter.
To visualize those neurons expressing 82-kDa ChAT following adenovirus
transduction, primary cortical neurons were seeded on poly-L-ornithine coated
confocal dishes (5 x 105 cells/dish) and grown for 6 days. Adenovirus was added
48 hours prior to processing for immunohistochemical analysis. Neurons were
fixed in 4% paraformaldehyde-PBS for 30 minutes at room temperate, followed
by blocking non-specific sites for 1 hour in PBS containing 0.05% Triton X-100
and 3% goat serum at room temperature. Neurons transduced with adenovirus
to express 82-kDa ChAT or R560H 82-kDa ChAT were co-labeled for neuronal
nuclear protein NeuN (mouse anti-NeuN antibody at 1:1000) and ChAT (rabbit
cTAB antibody at 1:1000). Cells were then incubated with goat anti-rabbit
secondary antibody conjugated to AlexaFluor 488 (1:500) and goat anti-mouse
secondary antibody conjugated to AlexaFluor 555 (1:1000) in blocking buffer for
1 hour at room temperature. Images were acquired with a Zeiss LSM 510 META
laser-scanning confocal microscope using a 63X objective. Immunofluorescence
of 82-kDa ChAT and R560H 82-kDa ChAT was visualized by 488 nm excitation
and 505-530 nm emission. NeuN immunofluorescence was visualized by 543
nm excitation and 560-615 nm emission.
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2.9 Quantitative real-time PCR
Total RNA was isolated from PBS (pH 7.4)-washed cortical neuron cultures
using the GeneElute kit (Sigma-Aldrich) at room temperature. RNA was reverse
transcribed using the iScript cDNA synthesis kit (BioRad). qRT-PCR was carried
out using the iQ SYBR Green Supermix (BioRad) on a BioRad CFX96 real-time
thermocycler. Forward and reverse primers used were murine specific at a final
concentration of 400 nM (Table 2.3). All genes were normalized to GAPDH and
the fold change was calculated based on the %%Ct method relative to GFPexpressing cortical neurons. Statistical analysis was performed on normalized Ct
values prior to transformation.

Table 2.3: Primers used for real-time PCR
Gene
APP
GGA3
BACE1
GAPDH
Sortilin 1
SNX6

Primers
Forward: AAGAACTTGCCCAAAGCTGA
Reverse: GTCTCTCATTGGCTGCTTCC
Forward: CAAAGGCTGAGCCCAAAGGT
Reverse: AGGGCACTGCTAGGCTTGAT
Forward: TGGACTGCAAGGAGACGGAG
Reverse: AACAGTGCCCGTGGATGACT
Forward: TTGTGATGGGTGTGAACCACGAGA
Reverse: CATGAGCCCTTCCACAATGCCAAA
Forward: CCCGGACTTCATCGCCAAG
Reverse: AGGACGAGAATAACCCCAGTG
Forward: TGCAGGTTACATTATCCCACCA
Reverse: GCCAGGTATTCAGCTTCCAGT

!

#'!

2.10 ChAT activity assay
Primary cortical neurons seeded on 35-mm dishes were transduced with
either GFP, 82-kDa ChAT or R560H 82-kDa ChAT encoding adenovirus. ChAT
activity was measured in total cell lysates using the radioenzymatic method of
Fonnum (1969) as modified by Rylett et al. (1993).

2.11 BACE1 activity assay
BACE1 activity was measured in lysates of cortical neuron cultures using
the "-secretase activity assay kit (BioVision), according to manufacturer’s
instructions. Relative fluorescence units (RFU) was used as a measurement of
BACE1 activity.

2.12 Human A" 1-42 ELISA
Total levels of human A"1-42 were measured in media recovered from
mouse cortical neuron cultures using the human A"1-42 ELISA kit (Invitrogen),
according to the manufacturer’s protocols. All values were normalized to total
protein concentrations of the cultures.

2.13 Luciferase promoter assay
Mouse SN56 cell were seeded at 30,000 cells in white 96-well plates and
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co-transfected using Lipofectamine 2000 (Invitrogen) with 0.2 µg of one of the
LightSwitch reporter GoClone plasmids (empty vector, R01, GAPDH or GGA3)
and 0.2 µg of either 82-kDa ChAT, R560H 82-kDa ChAT, 69-kDa ChAT or
pcDNA3.1 empty vector.

Sequence alignment between the human GGA3

promoter construct and the GGA3 data base shows a 100% sequence match.
R01 negative control reporter construct contains a 1kb non-conserved, nongenic, and non-repetitive fragment, while the GAPDH reporter construct served
as a positive transfection control. Detection of promoter activation was mediated
through the Renilla luciferase protein, which catalyzes oxidation of the
coelenterazine substrate and produces light at 480 nm. Reporter assays were
conducted 24 hours after transfection according to the LightSwitch luciferase
assay system protocol (SwitchGear Genomics).

Quadruplicate cell samples

were used in all experiments.

2.14 Data Analysis
Statistical analysis was carried out on GraphPad Prism 5 using Student’s ttests, or one-way ANOVA followed by Tukey’s, Dunnett’s or Bonferroni post-hoc
test where appropriate. All data are presented as mean ± SEM with statistically
significant differences determined as p < 0.05. Each n value represents the
number of independent experiments performed.
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CHAPTER THREE: RESULTS

3.1 Genotyping of APP/PS1 transgenic mouse litters
The experimental model that was used in most of the studies reported in
this thesis was cortical neurons cultured from the brains of APP/PS1 double
transgenic mouse embryos. These cultures allowed us to test hypotheses using
non-transformed

neurons

and

to

assess

the

effects

of

experimental

manipulations on the production of A" peptides that are released from these
neurons. These cultures also provided a control condition in each experiment for
comparison with the transgenic neurons since some of the mouse embryos in
each litter were non-transgenic mice. Tail clippings, taken from each embryo at
15 to 16 days of gestation, were digested and the genomic DNA was extracted
for genotyping, as described in the Methods section. As illustrated in the example
given in Figure 3.1, the genotyping PCR amplification reaction contained primers
specific for each of the two transgenes, mutant human APP and PS1, which
resulted in the production of amplicons of 350 bp and 608 bp in size respectively,
and to endogenous mouse FLOXG which led to the production of a 171 bp
amplicon as an internal control. Extraction buffer mixed with the PCR reaction
buffer was used as a negative control, as indicated in the (-) lane (Figure 3.1)
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Figure 3.1: Genotyping from APP/PS1 transgenic embryos. A representative
genotyping from one litter that had 8 embryos following breeding of a wild-type
female and double transgenic male mouse. Endogenous FLOXG (171 bp) was
used as a PCR control. Transgenic embryos were confirmed by the presence of
the APP and PS1 transgenes at 350 and 608 bp, respectively.
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3.2 Expression of adenovirus in primary cortical neurons
Expression of GFP, 82-kDa ChAT or catalytically inactive R560H 82-kDa
ChAT in primary cortical neurons was carried out using the adenoviral gene
delivery system. Images were taken 8 days after isolation, following a 48 hr
exposure of adenovirus. Figure 3.2 confirms that both the 82-kDa ChAT (Panel
B) and R560H 82-kDa ChAT (Panel C) are expressed in the nuclei of primary
cortical neurons at varying levels following adenoviral infection. Between 20 and
30% of neurons express wild-type or mutant ChAT at an MOI of 100. Cortical
neurons transduced with a GFP adenovirus were used as a control for this study
(Panel C). Further, 82-kDa ChAT is catalytically active in cortical neurons (93.85
nmol/mg/hr), where R560H 82-kDa ChAT lacks enzymatic activity (1.95
nmol/mg/hr) similar to GFP control (2.83 nmol/mg/hr) (Panel D).

3.3 A!1-42 release into culture media from APP/PS1 cortical neurons
Cortical neurons cultured from APP/PS1 transgenic mouse embryos
provide a valuable model for studying the regulation of and the effects of
experimental manipulations on the cellular metabolism of APP. To determine the
levels of human A"1-42 produced by and released from these neurons, a sensitive
ELISA was used to measure the levels present in the culture media. Figure 3.3
(Panel A) depicts a time-course of human A"1-42 levels in cultured media from
both transgenic (TG) and non-transgenic (NTG) mice at 4, 8, and 11 DIV.
small increase in the amount of A"1-42 was produced in the media from the TG

A
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Figure 3.2. Expression of adenovirus in primary cortical neurons. Primary
cortical neurons transduced for 48 h with GFP (Panel A), 82-kDa ChAT (Panel
B), or R560H 82-kDa ChAT (Panel C) adenovirus at an MOI of 100. 20 to 30%
of cortical neurons counterstained with NeuN, express GFP or ChAT. For ChAT
activity, data are expressed as mean of 2 independent experiments (Panel D).
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Figure 3.3. Human A!1-42 is released from APP/PS1 cortical neurons and is
reduced by 82-kDa ChAT expression. Panel A shows human A"1-42 levels
measured from cultured media of NTG and APP/PS1 TG cortical neurons by
ELISA.

TG neurons had a significant increase in A"1-42 release after 8 DIV

compared to NTG littermates (n=5). ***p<0.0001, Two-way ANOVA, Bonferroni
post-test.

Expression of 82-kDa ChAT resulted in a significant reduction in

soluble A"1-42 levels 8 DIV compared to control (Panel B). R560H 82-kDa ChAT
expression also reduced A"1-42 levels, but this was not significant compared to
control.

A"1-42 release was normalized to total protein concentration in cell

lysates (n=5). *p<0.05, One-way ANOVA with repeated measures, Tukey posttest (Fatima Abji).
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cultures at 4 DIV when compared to the NTG cultures (16.7 ± 7.8 versus 7.4 ±
3.2 pg/mL), but this was not found to be statistically significant. However at 8
DIV, there was a statistically significant increase in A"1-42 levels in the media
recovered from the culture of TG cortical neurons when compared to the NTG
cultures (284.8 ± 41.3 versus 5.2 ± 0.7 pg/mL). The level of A"1-42 continued to
rise in the media from the TG cultures at 11 DIV (909 ± 28.2 versus 6.5 ± 0.3
pg/mL), but as expected this was not seen in the NTG cultures.
Importantly, when either the wild-type human 82-kDa ChAT protein or the
catalytically-inactive mutant R560H 82-kDa ChAT protein was expressed in the
cortical neurons cultured from the TG mice there was a reduction in the amount
of human A"1-42 released into the culture media (Figure 3.3.B). Neurons were
transduced with adenovirus encoding either GFP, 82-kDa ChAT or R560H 82kDa ChAT and maintained in culture for 8 days, then culture media was collected
and the levels of A"1-42 measured by ELISA and normalized to the total protein
content in the cultures. Figure 3.3B displays a significant reduction in the amount
of A"1-42 in media from cultures expressing wild-type 82-kDa ChAT (3.13 ± 0.68)
compared to GFP-expressing control cultures (3.79 ± 0.83 pg/mL per µg protein)
(P < 0.05, One-way ANOVA with repeated measures). R560H 82-kDa ChAT had
a reduction in A"1-42 released in the media, but not significantly different from
GFP control (3.18 ± 0.69 pg/mL per µg protein).
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3.4

82-kDa ChAT alters mRNA and protein levels for APP processing-

related genes
Primary cortical neurons prepared from APP/PS1 transgenic mouse
embryos were virally-transduced to express either GFP, 82-kDa ChAT or the
catalytically-inactive R560H 82-kDa ChAT mutant. Importantly, real-time PCR
(qRT-PCR) analysis reveals a significant upregulation of GGA3 mRNA in
neurons expressing either 82-kDa ChAT (1.42 ± 0.11) or R560H 82-kDa ChAT
(1.57 ± 0.22) compared to GFP-expressing control neurons (Figure 3.4A). The
steady-state levels of either APP or BACE1 mRNA were not significantly altered
in neurons expressing either 82-kDa ChAT or R560H 82-kDa ChAT (Figure
3.4A).
Protein levels for GGA3, APP and BACE1 were measured by immunoblot
analysis with Immunoreactive band intensities quantified by densitometry and
normalized to sample actin immunoreactivity.

Consistent with the changes

observed for GGA3 mRNA, primary cortical neurons expressing either 82-kDa
ChAT or R560H 82-kDa ChAT had a significant increase in the steady-state
amount of GGA3 protein (1.55 ± 0.23 and 1.51 ± 0.25, respectively) compared to
GFP-expressing control neurons (0.92 ± 0.22). In sharp contrast to the findings
for GGA3 protein, there was a significant reduction in BACE1 protein levels in
neurons expressing either 82-kDa ChAT (0.93 ± 0.15) or R560H 82-kDa ChAT
(1.3 ± 0.31) when compared to GFP-expressing control neurons (1.84 ± 0.26).
APP levels remained unchanged in neurons expressing both 82-kDa ChAT (1.38
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Figure 3.4: Expression of 82-kDa ChAT and R560H 82-kDa ChAT alter
BACE1 and BACE1 trafficking protein levels in APP/PS1 cortical neurons.
mRNA (Panel A) and protein (Panel B) levels of APP, GGA3 and BACE1 were
measured in APP/PS1 primary cortical neurons transduced with adenovirus for
48 h at an MOI of 100. The BACE1 trafficking mediator gene, GGA3, is
upregulated in response to expression of both 82-kDa ChAT and R560H 82-kDa
ChAT. One-way ANOVA with Tukey’s test *p<0.05 (n=13). Protein levels of
APP, BACE1, and GGA3 were evaluated by immunoblot and showed an
upregulation of GGA3 following ectopic expression of 82-kDa ChAT and R560H
82-kDa ChAT. Conversely, BACE1 protein levels were significantly reduced in
these samples. *p<0.05, One-way ANOVA with Dunnett’s test (n=7). Panel C
shows a significant reduction in BACE1 activity measured by a fluorescence
assay in cortical neurons expressing both 82-kDa ChAT and R560H 82-kDa
ChAT. **p<0.01, *p<0.05, One-way ANOVA with Tukey’s test (n=5). Data has
been transformed and normalized to control, with raw values reported in the text.
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± 0.58) or R560H 82-kDa ChAT (1.16 ± 0.27) compared to GFP control (1.23 ±
0.55) (Figure 3.4B). BACE1 activity was also measured in primary cortical
neurons, and consistent with the findings of a reduction of BACE1 protein levels,
the enzyme activity was also significantly reduced in neurons expressing either
82-kDa ChAT (1382 ± 357.5 RFU/µg protein, p $ 0.01) or R560H 82-kDa ChATexpressing cells (1757 ± 412.5 RFU/µg protein, p $ 0.05) when compared to the
GFP-expressing control neurons (2421 ± 568.4 RFU/µg protein) (Figure 3.4C).

3.5 82-kDa ChAT does not alter expression of all protein trafficking genes
The trafficking of BACE1 to lysosomes in conjunction with the actions of
GGA3 plays an important role in maintaining its cellular levels and mediates its
degradation (Tesco et al., 2007). Previous studies have further linked both SNX6
as a negative modulator of BACE1 transport (Okada et al., 2010) and Sortilin 1
as a retrograde transporter of BACE1 from the endosomes to the trans-Golgi
network (TGN) (Finan et al., 2011). To determine whether the expression of 82kDa ChAT protein in neurons has a generalized effect on proteins involved in
trafficking, we investigated the effect of expressing either 82-kDa ChAT or
R560H 82-kDa ChAT on two other trafficking proteins, SNX6 and SORT1, at the
mRNA level. Figure 3.5 reveals that neither 82-kDa ChAT nor R560H 82-kDa
ChAT significantly altered steady-state SNX6 or SORT1 transcript levels in
primary cortical neurons when compared to GFP-expressing control neurons.
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Figure 3.5: The trafficking genes, SORT1 and SNX6 were unchanged in
response to overexpression of both 82-kDa ChAT and R560H 82-kDa ChAT
in cortical cultures form APP/PS1 mice.
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3.6 Chloroquine treatment restores BACE1 protein levels in ChAT
expressing neurons
GGA3 has been shown to interact directly with ubiquitinated BACE1 and
target it to the lysosome for degradation (Kang et al., 2010). To determine if the
reduction in BACE1 levels observed in our studies in 82-kDa ChAT expressing
neurons was the result of lysosomal degradation of the protein, APP/PS1 primary
cortical neurons were treated with chloroquine, which deacidify lysosomes and
reduces the activity of many lysosomal enzymes. In these experiments, APP/PS1
cultured neurons were transduced with adenovirus encoding either 82-kDa
ChAT, R560H 82-kDa ChAT or GFP on day six in culture, then treated with 25
µM chloroquine for 18 hours prior to being harvested and lysates prepared for
immunoblots for BACE1 protein analysis. As illustrated in Figure 3.6, cultured
cortical neurons expressing either 82-kDa ChAT (0.96 ± 0.05) or R560H 82-kDa
ChAT (0.93 ± 0.08) and treated with vehicle had a statistically significant
reduction in BACE1 protein levels when compared to GFP-expressing control
cells (1.25 ± 0.05). By comparison, chloroquine treatment of neurons expressing
either 82-kDa ChAT or R560H 82-kDa ChAT attenuated the reduction in BACE1
protein levels, and restored BACE1 protein to control levels (1.23 ± 0.09 and 1.38
± 0.08 respectively). There was a small increase in BACE1 levels in control
neurons expressing GFP with chloroquine treatment (1.37 ± 0.07) (Figure 3.6).
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Figure 3.6: Lysosomal inhibition restores BACE1 protein levels. Inhibition of
lysosome function using 25µM Chloroquine for 18 hours results in attenuation of
the effect of expressing 82-kDa ChAT in cultured neurons as demonstrated by an
increase in BACE1 protein levels. *p<0.05, one-way ANOVA (n=7). Data has
been transformed and normalized to control, with raw values reported in the text.
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3.7 GGA3 knockdown restores BACE1 protein levels in 82-kDa ChAT
expressing neurons
To assess further if the reduction of BACE1 protein levels and activity
observed in cultured neurons expressing 82-kDa ChAT is mediated by a
mechanism that involves GGA3, cortical neurons were treated with lentivirus that
encodes an shRNA targeting GGA3 transcripts with no known cross-reactivity
based on sequence analysis. Control neurons were transduced with a lentivirus
encoding GFP (copGFP lentivirus). Figure 3.7A shows that the GGA3 protein
levels were significantly increased in cultured neurons expressing 82-kDa ChAT
when compared to GFP-expressing neurons (1.82 ± 0.35 and 1.20 ± 0.17,
respectively. #p<0.05); in this experiment, both the 82-kDa ChAT and GFP
expressing neurons were transduced with the copGFP lentivirus control virus. As
predicted, neurons transduced with the GGA3 shRNA lentivirus had significant
reductions in endogenous GGA3 protein levels to about 50% of control (Figure
3.7A). Figure 3.7B shows the effect of GGA3 knockdown on BACE1 protein
levels. Consistent with our previous results (Figure 3.4B), in cultured cortical
neurons treated with the control lentivirus copGFP, expression of 82-kDa ChAT
resulted in a significant reduction in BACE1 protein level when compared to
GFP-expressing control neurons (0.97 ± 0.12 and 1.39 ± 0.03, respectively).
Importantly, the reduction in GGA3 protein levels caused by knockdown with the
shRNA restored BACE1 protein levels in 82-kDa ChAT expressing neurons to
the level of that found in GFP-expressing control neurons. Furthermore, BACE1
activity was measured and its activity in 82-kDa ChAT expressing neurons was
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Figure 3.7: GGA3 knockdown recovers BACE1 protein levels in 82-kDa
ChAT expressing neurons.

Primary cortical neurons infected with 82-kDa

ChAT and a copGFP control lentivirus had a significant increase in GGA3
expression (#p<0.05). Transfection of lentiviral shRNA targeting GGA3 resulted
in a 50% reduction in expression levels (A).

The reduction in GGA3 levels

resulted in attenuation of the effect of expressing 82-kDa ChAT in cultured
neurons as demonstrated by an increase in BACE1 protein levels (B) *p<0.05,
one-way ANOVA (n=7).

BACE1 activity was also recovered close to control

levels following GGA3 shRNA treatment (C) *p<0.05, one-way ANOVA (n=10).
Data has been transformed and normalized to control, with raw values reported
in the text.
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recovered to close to control levels following GGA3 knockdown (Figure 3.7C).

3.8 82-kDa ChAT activates the GGA3 promoter
The next set of experiments was designed to determine whether 82-kDa
ChAT plays a role in regulating GGA3 gene expression. To accomplish this, we
obtained a promoter construct containing about 1 kilobase of the proximal
promoter of the human GGA3 gene driving a luciferase reporter gene
(SwitchGear Genomics). Both negative (RO1) and positive (GAPDH) control
luciferase promoter constructs were included in these experiments. These control
constructs and the GGA3 promoter construct were transfected individually into
SN56 cells. Cells were co-transfected with plasmids encoding either wild-type 82kDa ChAT, R560H 82-kDa ChAT, 69-kDa ChAT, or empty pcDNA3.1 vector as a
control, then the effect on promoter activation was determined by measuring
luciferase activity. Figure 3.8A shows that the expression of either 82-kDa ChAT,
R560H 82-kDa ChAT or 69-kDa ChAT resulted in a statistically significant
increase in the GGA3 promoter-luciferase activity (33789 ± 3217, 32526 ± 2150,
and 31837 ± 3525, respectively) when compared to the empty vector control cells
(23153 ± 2461). Expression of 82-kDa ChAT, R560H 82-kDa ChAT and 69-kDa
ChAT was measured and luciferase activity relative to protein expression was
assessed. 69-kDa expresses at a higher level relative to both 82-kDa ChAT and
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Figure 3.8. SN56 cells expressing 82-kDa ChAT, R560H 82-kDa ChAT and
69-kDa ChAT were able to induce luciferase activity through the GGA3
promoter. (A) Expression of 82-kDA ChAT, R560H 82-kDa ChAT and 69-kDa
ChAT resulted in a significant increase in luciferase activity through the GGA3
promoter compared to empty vector control. *p<0.05, one-way ANOVA (n=4).
(B) Both 82-kDa ChAT and R560H 82-kDa ChAT display a 2-fold increase in
GGA3 promoter activation compared to 69-kDa ChAT based on their relative
expression levels.

(C) SN56 cells transfected with empty vector control

displayed no ChAT expression (Lane 3).
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R560H 82-kDa ChAT, which may account for the high level of GGA3 promoter
activation (Figure 3.8C). Transformation of luciferase activity relative to protein
expression resulted in a 2-fold increase in GGA3 promoter activation through 82kDa ChAT and R560H 82-kDa Chat compared to 69-kDa ChAT (Figure 3.8B).

3.9 APP processing is not altered in cell lines
The effect of 82-kDa ChAT expression on APP processing was also
examined in various neural cell lines, including SH-SY5Y, N2A and SN56 cells
(Figure 3.9). SH-SY5Y cells ectopically expressing 82-kDa ChAT did not show
either an increase in GGA3 protein levels or a reduction in BACE1 protein levels
that was observed in cultured mouse brain cortical neurons. Endogenous levels
of BACE1 protein were found to be quite low in SH-SY5Y cells when compared
to N2A and SN56 cells (Figure 3.9A). N2A cells ectopically expressing 82-kDa
ChAT displayed no increase in GGA3 protein levels or a reduction in BACE1
protein, similar to the SH-SY5Y cells (Figure 3.9B).

In contrast, SN56 cells

expressing 82-kDa ChAT show a small increase in GGA3 protein levels, but
BACE1 levels remain unchanged compared to control cells (Figure 3.9C).

!

%&!

Figure 3.9. Expression of 82-kDa ChAT in multiple cell lines does not alter
BACE1 or BACE1 trafficking protein levels. SH-SY5Y (A) and N2A (B) cells
transfected with 82-kDa ChAT cDNA expression vector show no increase in
GGA3 protein levels or a subsequent reduction in BACE1 protein levels
compared to cells transfected with empty vector control. (C) SN56 cells have a
small increase in GGA3 protein levels when expressing 82-kDa ChAT, but no
change in BACE1 protein levels.
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3.10 Oxidative stress induces alterations in ChAT structure and localization
ROS levels are elevated in AD in response to soluble A" levels (Huang et
al., 1999), and they can have detrimental effects on protein structure and
function, potentially through the formation of disulfide bonds at Cys residues.
Given that ChAT has a high number of solvent exposed Cys residues, it was
asked if ROS mediated oxidation of Cys residues has an effect on ChAT
structure, function and subcellular localization. HEK 293 cells expressing myctagged 69-kDa ChAT or FLAG-tagged 82-kDa ChAT were treated with increasing
concentrations of the oxidative agent hydrogen peroxide (H2O2). It was shown
that there was a concentration dependent effect on higher molecular weight
(HMW) structure formation under non-reducing conditions of 69-kDa ChAT
(Figure 3.10) and an increase in 82-kDa ChAT HMW structures at higher
concentrations of H2O2 (Figure 3.11). Further, this effect was reversed with the
addition of reducing agents dithiothreitol and 2-mercaptoethanol that break
disulfide bonds.
Many proteins, including GAPDH have altered subcellular localization in
response to oxidative stress and disulfide formation (Cumming and Schubert,
2005). It has been also found that 82-kDa ChAT exhibits decreased nuclear
localization in patients with MCI and AD, through mechanisms currently unknown
(Gill et al., 2006).

Here we investigated the effect of A"1-42 treatment on

cytoplasmic 82-kDa ChAT localization following a 5-day treatment on stable SHSY5Y cells. A concentration dependent increase in cyoplasmic 82-kDa ChAT
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Figure 3.10. Oxidative stress alters 69-kDa ChAT structure. Under nonreducing conditions, 69-kDa ChAT forms concentration dependent higher
molecular weight structures following H2O2 treatment. These structures are lost
with the addition of reducing agents.
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Figure 3.11. Oxidative stress alters 82-kDa ChAT structure. Under nonreducing conditions, 82-kDa ChAT forms higher molecular weight structures at
increasing concentrations of H2O2. These structures are lost with the addition of
reducing agents.
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Figure 3.12. A!1-42 induces changes 82-kDa ChAT localization.
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Stable

expressing 82-kDa ChAT SH-SY5Y cells treated with A"1-42 for 5 days display a
concentration dependent change in ChAT localization. Under vehicle treatment,
82-kDa ChAT is localized in the nucleus. Increasing the concentration to 500
nM, ChAT is observed to change localization to the cytoplasm of SH-SY5Y cells.
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staining was observed in the 100 and 500 nM A"1-42 treated SH-SY5Y clonal
cells compared with vehicle control (Figure 3.12).

!

&"!

CHAPTER 4: DISCUSSION

4.1

Significant findings
The goal of this study was to further investigate the link between the

expression of 82-kDa ChAT in neurons and changes in the expression of genes
involved in the amyloidogenic processing of APP. Previous studies from our
laboratory demonstrated that ectopic expression of 82-kDa ChAT in cortical
neurons derived from embryonic double transgenic mice that express mutant
human forms of both APP and PS1 led to a reduction in the amount of A" that is
released from the neurons into the culture media. In addition, we were interested
in investigating the effect of acute exposure of neurons to A" on 82-kDa ChAT
structure and localization; A" can lead to increased ROS production in cells and
oxidation of cellular constituents including proteins.
Here we demonstrate that increased expression of human nuclear 82-kDa
ChAT and catalytically-inactive R560H 82-kDa ChAT alter APP processing genes
that promote a reduction in BACE1 activity and expression resulting in reduced
A" production. Expression of both ChAT proteins in primary neurons resulted in
upregulation of both the GGA3 transcript and protein levels, while BACE1 protein
levels were reduced. Inhibition of the lysosome with chloroquine treatment and
knockdown of GGA3 through lentiviral shRNA, was found to recover BACE1
protein levels back to control levels.

GGA3 promoter analysis through a

luciferase assay indicates that both 82-kDa ChAT and R560H 82-kDa ChAT are
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able to directly or indirectly activate transcription of the GGA3 1037 bp promoter
sequence.
We were also able to demonstrate a direct oxidative effect on both 69- and
82-kDa ChAT structure, as well as a localization change of 82-kDa ChAT
following A"1-42 treatment. HEK293 cells expressing 69- or 82-kDa ChAT, when
treated with increasing concentrations of H2O2, show a concentration dependent
increase in higher molecular weight ChAT species under non-reducing
conditions.

Addition of a reducing agent that can break disulfide bonds,

eliminated the high molecular forms of ChAT. Finally, 5-day treatment of SHSY5Y cells stably expressing 82-kDa ChAT with A"1-42 showed a concentration
dependent localization change, favoring cytoplasmic staining at higher levels of
A"1-42.

4.2 Contribution to current knowledge of 82-kDa ChAT
The role and function of 69-kDa ChAT as an ACh synthesizing enzyme in
cytoplasm of cholinergic neurons has been studied widely. The significance of a
nuclear isoform of ChAT acting as a potential regulator of gene expression,
however, has become a topic of study only recently.

Matsuo et al. (2010)

demonstrated recently that 82-kDa ChAT can act as an activator of transcription,
specifically of the high-affinity choline transporter (CHT1). Previous studies in our
laboratory indicate a possible role for ChAT in reducing both BACE1 protein
levels and A" secretion (unpublished data).

The current studies provide
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additional support for a nuclear function of ChAT, in which it interferes with the
amyloidogenic pathway through upregulation of the GGA3 protein. GGA3 has
been linked to the APP processing pathway as a negative regulator of BACE1
through a direct interaction in which GGA3 binds to and targets ubiquitinated
BACE1 to the lysosome for degradation (Kang et al., 2010).

Here, we

demonstrate that both wild-type 82-kDa ChAT and the catalytically-inactive
mutant R560H 82-kDa ChAT regulate GGA3 at the level of transcription and this
is mediated through an action at the level of the GGA3 promoter.

It is still

unknown whether the activation is via a direct or indirect mechanism. There is
preliminary evidence that 82-kDa ChAT can bind directly to DNA. Our laboratory
is currently investigating the ability of 82-kDa ChAT to bind directly DNA using
both confocal microscopy and ChIP analysis. Analysis of the three-dimensional
structure of ChAT shows a row of basic amino acid residues that lie along the
surface of the protein and may be able to bind directly to the minor groove of
DNA, at A-T rich regions. In preliminary studies, cells immunostained for 82-kDa
ChAT show localization around DNA that is displaced by increasing
concentrations of Hoechst (33342) dye, a nuclear stain that has the ability to
displace proteins bound to the minor groove of DNA.
In the current study, we found that expression of a catalytically-inactive
mutant of 82-kDa ChAT in neurons had the same affect as expression of the
wild-type enzyme in all of the assays performed. This differs from the findings of
Matsuo and colleagues (2010) in that they used a catalytically-inactive mutant of
ChAT and obtained results that differed from those obtained with the wild-type
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enzyme. In their study, Matsuo et al. (2010) did not find activation of the CHT1
gene in cells expressing inactive 82-kDa ChAT, whereas we demonstrate that
catalytically-inactive 82-kDa ChAT maintains its ability to increase GGA3 levels.
While these studies focused on the activation of two separate genes, it is also
important to consider whether there may be potential differences between the
two different mutant ChAT proteins expressed.

We created a catalytically-

inactive ChAT protein by mutating arginine 560 to histidine (R560H in 82-kDa
ChAT, R442H in 69-kDa ChAT), which was reported as a spontaneously
occurring mutant form of ChAT caused by a single nucleotide polymorphism
(SNP) in individuals with congenital myasthenic syndrome that leads to apnea,
paralysis, and death (Ohno et al. 2001; Dobransky et al. 2003). This mutation is
found adjacent to the catalytic domain of ChAT, and it severely interrupts the
activity of the enzyme by decreasing the affinity for binding of the co-substrate
acetyl-CoA (Ohno et al., 2001). Moreover, our laboratory demonstrated that this
mutant does not undergo protein kinase C-mediated phosphorylation of serine440 which is also required for maintenance of optimal enzyme catalytic activity
(Dobransky et al., 2004). Matsuo et al. (2010) created a mutant ChAT protein in
which glutamic acid at residue 441 was substituted by a lysine residue (E441K).
While this enzyme was catalytically-inactive, it also is expressed at a much lower
level than either wild-type 82-kDa ChAT or the mutant R560H 82-kDa ChAT
(Ohno et al. 2001). Interestingly, the study published by Matsuo et al. (2010)
shows that this mutant is expressed at a low level, but they do not comment on
how this may have affected their results. While it is unclear if glutamic acid 441 is
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necessary for ChATs genetic regulation, either the stability or expression of this
form of 82-kDa ChAT may account for the lack of effect on CHT1 expression.
We investigated the link between the expression of 82-kDa ChAT in
neurons and the modulation of the GGA3-mediated BACE1 trafficking pathway
further by interfering with other potential components of the system. We first
focused on the effects of inhibiting the function of the lysosome through
chloroquine treatment, which prevents endosomal acidification and decreases
protein degradation. This in turn inhibits the function of lysosomal proteins and
the fusion of endosomes with lysosomes, which require an acidic environment
(De Duve, 1983). Chloroquine treatment has been previously shown to disrupt
the lysosomal protein degradation pathway and elevate endogenous BACE1
levels in multiple cell types, including primary neurons (Koh et al., 2005). Here
we demonstrate that treating cortical neurons cultured from APP/PS1 transgenic
mice that express either 82-kDa ChAT or R560H 82-kDa ChAT with chloroquine
can restore BACE1 protein levels to those observed in control neurons that do
not express 82-kDa ChAT. Previous studies that investigated the mechanisms
by which BACE1 protein is degraded provide conflicting results. One study
shows that BACE1 is turned over through the ubiquitin-proteasome pathway,
although these investigators did not test lysosomal inhibitors on BACE
degradation as a control (Qing et al., 2004). These findings were challenged by
Koh et al. (2005) who found that lysosomal inhibitors and not proteasome
inhibitors cause an elevation in BACE1 protein levels, therefore suggesting that
BACE1 is degraded in the lysosome.
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It has been shown that experimental conditions that lead to a decrease in

the level of GGA3 protein can result in elevation of BACE1 protein levels (Tesco
et al., 2007). Samples from the temporal cortex of brains of individuals diagnosed
with AD show a reduction in GGA3 protein levels that correlate inversely with
increased BACE1 levels (Tesco et al., 2007). In the present studies, we
demonstrate that shRNA-mediated reduction of GGA3 protein levels in cultured
cortical neurons expressing 82-kDa ChAT results in elevated BACE1 protein
levels similar to those observed in control neurons not expressing 82-kDa ChAT.
GGA3 regulates BACE1 trafficking between the cell membrane and the TGN, as
well as its transport to the lysosome for degradation mediated through a direct
interaction of GGA3 with ubiquitinated BACE1.

Depletion of cellular GGA3

protein interrupts the trafficking to both the lysosome and the TGN causing an
accumulation of BACE1 in the early endosomes. The acidic environment of the
early endosomes results in increased "-secretase activity of BACE1, thereby
promoting increased amyloidogenic cleavage of APP and production of A" (Kang
et al., 2010). While we did not observe a significant increase in BACE1 activity
following GGA3 protein knockdown, future studies should investigate if there are
changes in BACE1 localization in early endosomes in this model. Finally, we
investigated the effect of expression of 82-kDa ChAT in the cultured cortical
neurons on the expression of two other trafficking genes that are known to
interact directly with BACE1 to determine if the ChAT-induced effects on BACE1
trafficking are more generalized. Sortilin facilitates the retrograde transport of
BACE1 from the endosome to the TGN and promotes the interaction of APP and
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BACE1, thereby increasing the production of A" (Tan and Evin, 2012). SNX6
promotes the trafficking of BACE1 in a manner that perturbs the accumulation in
the TGN and reduces the interaction between APP and BACE1 (Okada et al.,
2010). In both instances, the expression of 82-kDa ChAT in neurons had no
effect on the expression of the genes for these two other known BACE1
trafficking genes, indicating that the effect noted for GGA3 is a specific effect in
terms of the trafficking proteins monitored.
We also found that the effects mediated by 82-kDa ChAT on the activation
of expression of some genes is cell specific. This was also observed in the
studies reported by Matsuo et al. (2010) where CHT1 activation was observed in
neuronal cells expressing 82-kDa ChAT, but not in HEK293 cells. Here, we
demonstrate a cortical neuron-specific effect of 82-kDa ChAT on the expression
of GGA3, but there was no effect in transformed neural cell lines that were
tested. The reasons for this cell-specific effect of 82-kDa ChAT are not known,
but cortical neuron specific activation of selected genes may be in place to
compensate for the enhanced APP processing that takes place in this transgenic
mouse model of AD.
To summarize, our results demonstrate a cell-specific secondary function of
ChAT by which nuclear 82-kDa ChAT can facilitate genetic regulation through an
upregulation of GGA3 at the mRNA and protein levels.

This translates to a

reduction in BACE1 protein and activity levels, mediated through enhanced
lysosomal degradation of BACE1, culminating in a reduction in A" generation
and secretion. This is illustrated in the schematic shown in Figure 4.1.
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Figure 4.1: Proposed mechanism of nuclear 82-kDa ChAT regulation of APP
processing. 82-kDa ChAT expression causes upregulation of GGA3 mRNA and
protein which functions to target BACE1 for lysosomal-mediated degradation and
decreased amyloidogenic processing.
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Contribution to the effect of oxidative stress on ChAT
Increased levels of oxidative stress in the human AD brain are well

documented (Markesbery, 1996). A range of cellular changes show that oxidative
stress precedes any of the hallmark characteristics of AD, including A"
deposition and neurofibrillary tangle formation. A", particularly toxic A"1-42, is
involved both directly and indirectly in the generation of ROS, which can cause
the oxidation of lipids and proteins (Butterfield and Bush, 2004; Lahiri and Greig,
2004). Modification of reactive Cys thiols occurs during oxidative stress and can
result in either a loss-of-function or gain-of-function for many proteins (Klatt and
Lamas, 2001). Importantly, human ChAT has a higher than usual content of Cys
residues, with 20 and 24 Cys residues in the 69-kDa and 82-kDa enzymes
respectively, making it particularly vulnerable to oxidative stress.

Here we

investigated the effect of oxidative stress, both directly (H2O2) and indirectly (A"142)

on ChAT structure.

Both 69- and 82-kDa ChAT were shown to have a

concentration dependent increase in the abundance of higher molecular mass
structure formation under non-reducing conditions.

Addition of the reducing

agents dithiothreitol and 2-mercaptoethanol, agents which promote breakage of
disulfide bonds, eliminated the higher molecular mass ChAT structures. These
results are suggestive of an oxidation-dependent change in ChAT protein
structure that may be mediated through oxidation at reactive Cys residues.
A decline in ChAT function has been linked to oxidative stress-mediated
mechanisms initiated by A" oligomers, with this effect on ChAT activity reversed
through the addition of antioxidant agents (Nunes-Tavares et al., 2012). At low
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nanomolar concentrations of A" oligomers, ChAT activity can be reduced up to
50%, but this occurs in the absence of any evidence of neuronal damage or
death (Nunes-Tavares et al., 2012). Moreover, there is growing evidence linking
the ability for A" oligomers to activate the NMDA receptor and an increase in
intracellular ROS levels (De Felice et al., 2007). In association with this, it was
found that blocking the binding of A" oligomers to NMDA receptors by the AD
drug memantine significantly reduced cellular ROS levels (De Felice et al., 2007).
Taken together, reduction in ChAT activity mediated by A" oligomer-induced
oxidative stress may be an early event in the development of AD pathology.
Further study should investigate whether the formation of higher molecular mass
ChAT species directly results in the decline in ChAT activity.
It has been demonstrated that there is decreased amounts of
immunoreactive 82-kDa ChAT protein in nuclei of cholinergic neurons in
necropsy brain from individuals diagnosed with MCI or early AD, but the
mechanisms underlying this are currently unknown (Gill et al., 2007). Cumming
and Schubert (2005) demonstrated that long-term treatment of cultured cells with
A" can cause an oxidation-dependent change in the subcellular localization of
GAPDH. In these studies, it was shown that GAPDH becomes oxidized to form
dimers through disulfide linkage, and then can be readily shuttled into the
nucleus to become a proapoptotic factor (Cumming and Schubert, 2005).
Importantly, in the studies reported in this thesis, we demonstrate that with acute
exposure of neural cells to A" oligomers, 82-kDa ChAT may undergo oxidation.
Moreover, ChAT oxidation is associated with an A" oligomer concentration-
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dependent change in its subcellular localization, favoring a predominately
cytoplasmic localization similar to that seen in older individuals and in MCI and
AD patients.
In summary, further study needs to be carried out to determine the cellular
mechanisms that regulate changes in the subcellular, cytoplasmic versus
nuclear, localization of 82-kDa ChAT.
compartmentalization

of

82-kDa

ChAT

If the changes in subcellular
is

a

result

of

dimerization

or

oligomerization of the protein mediated by oxidative stress, then determining if
this may potentially involve other cellular interacting or binding proteins with 82kDa ChAT may give a better insight into the localization change. Finally, we
demonstrated here that 82-kDa ChAT can elicit an effect on gene expression
while located in the nucleus. If long-term changes in the oxidation state in the
brain microenvironment can cause changes in the subcellular localization of 82kDa ChAT, then it should be determined if the protective effect of 82-kDa ChAT
expression against amyloidogenic APP processing is lost as a result of increased
cellular ROS levels and post-translational oxidation of ChAT.

4.4

Conclusions
To our knowledge, this is the first time 82-kDa ChAT has been directly

linked to regulation of components of the amyloidogenic APP processing
pathway. Nuclear 82-kDa ChAT is able to cause a reduction in both BACE1
protein and activity and in A" levels in cortical neurons from APP/PS1 double
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transgenic mice, mediated through regulation of the GGA3 trafficking protein, and
independent of ChAT enzymatic activity. Both the inhibition of lysosome function
and knockdown of GGA3 protein levels were able to restore BACE1 protein
levels to control levels in neurons expressing 82-kDa ChAT. Finally, short-term
and long-term oxidative stress are able to alter ChAT structure and subcellular
localization, respectively.

Under normal cellular conditions, 82-kDa ChAT is

localized to the nucleus of neurons and is able to regulate GGA3 gene
expression and protein levels and cause a reduction in BACE1 protein levels,
thereby reducing the level of A" secretion into media bathing cultured neurons
expressing mutant human APP and PS1. It can be hypothesized that as AD
pathology progresses and the level of cellular ROS increases, the subcellular
localization of 82-kDa ChAT in cholinergic neurons changes to a predominately
cytoplasmic localization. Further study should focus on the events that lead to
either the loss of nuclear import of 82-kDa ChAT or increases in its nuclear
export, and whether this ultimately results in a loss of its effects on the regulation
of gene expression.

4.5

Limitations of the Research
The major limitation for the present study was achieving consistent

expression of the GFP and ChAT adenovirus in neurons cultured from mouse
brain cortex. Using an adenoviral gene delivery system was the most effective
approach for these studies, but this system was only able to yield approximately
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20-30% transduction efficiency at an MOI of 100.

A lower MOI produced a

reduced yield of expressing cells and a higher MOI became toxic to the neurons.
During the knockdown experiments, neurons co-transfected with both a lentivirus
and adenovirus had a reduced level of co-expression, which may account for the
smaller changes observed for several measures and the greater variability in
data, for example in the BACE1 activity assays. Finally, cultures with higher than
normal astrocyte levels display lower neuronal expression of adenoviral
expressed genes as a result of being taken up more readily by the astrocyte
population.

To overcome this, our lab is in the process of developing a

transgenic mouse strain in which Floxed 82-kDa ChAT is expressed in forebrain
cholinergic neurons and crossing with Cre-driver mice.

This will remove the

variable expression between cultures and provide a better model to study the
effect of 82-kDa ChAT expression on the APP processing pathway.
The effect of long term exposure to A" on 82-kDa ChAT structure and
subcellular localization in primary cortical neurons could not be carried out as a
result of a limited expression period of the adenovirus. Expression of 82-kDa
ChAT in primary neurons peaked between 2 and 3 days post-transfection,
thereby limiting their ability to be used in experiments requiring a 5 day test
period. Finally, the generation of a lentiviral delivery system for expression of 82kDa ChAT or the creation of knock-in mice that express 82-kDa ChAT in neurons
would allow for and extended time point analysis of A"-induced oxidative stress
on 82-kDa ChAT localization in cultured neurons. Offspring of a 82-kDa ChAT X
Cre mouse crossed with a APP/PS1 mouse could also give insight into the long-
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term effect of 82-kDa ChAT expression in AD and to possible subcellular
localization alterations resulting from an overactive amyloidogenic pathway.

4.6

Future Studies
The studies reported in this thesis demonstrate a novel role for both 82-

kDa ChAT and R560H 82-kDa ChAT in regulation of the APP processing
pathway. The present data indicates that nuclear localized ChAT is able to drive
activation of the GGA3 promoter, resulting in increased levels of GGA3 mRNA
and protein.

Determining whether this effect of 82-kDa ChAT is mediated

through a direct interaction with DNA or by an indirect interaction, possibly
mediated through transcription factor cascade or other regulatory proteins, is an
important next step.
Short term ROS treatment to cells expressing both 69- and 82-kDa ChAT
showed a concentration-dependent increase in higher molecular mass ChAT
structures. While some of the higher molecular mass structures coincide with a
molecular weight that would suggest homo-dimerization, there are oxidized forms
of ChAT that may have dimerized with other cellular proteins. Redox 2D SDSpage to separate possible proteins that form mixed disulfide bonds with ChAT as
a result of oxidation may give insight into the cause of both a reduction in ChAT
activity and localization change observed from both short- and long-term
oxidative stress.
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The generation of a transgenic knock-in model of 82-kDa ChAT will allow

for further and more complete analysis of the role of this cholinergic neuronal
enzyme in role in APP processing. A major limitation in the present studies was
consistent adenovirus expression of ChAT proteins, which would be overcome by
generation of knock-in mice model. Further, the effect of long-term A" exposure
to neurons expressing 82-kDa ChAT could be examined using progeny of a
knock-in mouse crossed with an APP/PS1 transgenic mouse.
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